📰 Study Sites News
Page 2 - Study Sites News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Study Sites. Real-time updates on events, politics, business and more.
February 21, 2023
/PRNewswire/ -- 3H Medi Solution Inc., a leading Japanese clinical trial company, today announced its selection of THREAD to expand decentralized research...
November 30, 2022
30.11.2022 - TORONTO, Nov. 29, 2022 (GLOBE NEWSWIRE) - Theralase Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic ...
August 30, 2022
TORONTO, Aug. 29, 2022 (GLOBE NEWSWIRE) — Theralase
June 21, 2022
TORONTO, June 21, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage...
May 31, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
May 30, 2022
TORONTO, May 30, 2022 (GLOBE NEWSWIRE) — Theralase ® Technologies Inc. (“ Theralase ” or the “ Company ”) ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage…
February 10, 2022
This randomized clinical trial assesses the effect of intra-arterial alteplase infusion vs placebo on functional outcomes (modified Rankin Scale scores) among p
July 23, 2021
Institute for Environmental Studies (IVM), Vrije Universiteit, Amsterdam, Netherlands Nature-based solutions (NBS) provide a promising means to a climate resilient future. To guide investments in NBS, stated preference studies have become a common tool to evaluate the benefits of NBS in developing countries. Due to subsistence lifestyles and generally lower incomes, SP studies in developing countries increasingly use time payments as an alternative to the traditionally implemented money payment...
April 27, 2021
Theralase Technologies Inc.: Theralase Releases Quarterly Newsletter ® Technologies Inc. (" TSXV:TLT)( OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (" PDC") and associated drug formulations to safely and effectively destroy various cancers, bacteria and viruses has released the Companys Quarterly Newsletter (" Newsletter") which provides updates on the previous quarter and progress on the Phase II Non...
February 24, 2021
Theralase Technologies Inc.: Theralase Launches Fifth Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study Theralase" or the " TSXV:TLT)( OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (" PDC") and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that University of Wisconsin Health-Madison (" UWH") has receiv...